乐虎lehu国际
Home
乐虎lehu国际:Science&Technology
乐虎lehu国际:Research Areas
乐虎lehu国际:Technology Platform
乐虎lehu国际:Products
乐虎lehu国际:Product Center
乐虎lehu国际:Pipeline Progress
乐虎lehu国际:Media News
乐虎lehu国际:Press_releases
乐虎lehu国际:Media_Images
乐虎lehu国际:IR
乐虎lehu国际:Fact Sheet
乐虎lehu国际:Ir Calendar
乐虎lehu国际:Interactive Analysis Tool
乐虎lehu国际:Share Graph
乐虎lehu国际:Share Price Alters
乐虎lehu国际:Annual Report Download
乐虎lehu国际:Lost Share Certificate
Announcements & Circulars
乐虎lehu国际:Email Subscription Center
Faqs
乐虎lehu国际:Dissemination of Corporate Communications
乐虎lehu国际:About Us
Profile
乐虎lehu国际:Leadership
乐虎lehu国际:Partnering
CSR
IP
Honor
乐虎lehu国际:
EN
乐虎lehu国际:
简
乐虎lehu国际:
繁
Media
PRESS RELEASES
Home
Media
乐虎lehu国际:PRESS RELEASES
Co-Construction of Healthcare Facilities for better Chronic Disease Management in the Greater Bay Area,Letter of Intent for Strategic Cooperation Framework Signed Between Uni-Bio
2019-06-14
乐虎lehu国际:View details
Uni-Bio Group (HK690)’s Uni-PTH (Teriparatide) High-Precision Industrialization Project Was Successfully Approved Focus on the Transformation of Major Frontier Achievements Targeting the Tens of Billions Osteoporosis Market
2019-04-17
乐虎lehu国际:View details
2018 Annual Results Announces: Enhanced Market Penetration of Core Marketed Products Pipeline Products Witnessed a Steady Progress to Launc Commencement of CMO Service to Fully Harness Asset Value
2019-03-29
乐虎lehu国际:View details
The Group Sets Up Top-Tier Production Lines At Beijing Genetech Pharm to Commence 3-in-1 CMO Services As a Move to Harness Asset Values for Revenue Expansion Fully Utilizing Its Production Capabilities and Enhancing Overall Competitiveness
2019-01-27
乐虎lehu国际:View details
Uni-Bio Science’s Anti-diabetic Acarbose Oral Tablets BE Study Application Accepted by the National Medical Products AdministrationSolid Progress to Fuel Product Launch, Ready to Tap into RMB10 billion Market
2019-01-04
乐虎lehu国际:View details
1...
<<
7
8
9
10
11
>>
16
Hot news
2024-01-22
As A Breakthrough Drug For The Expansive Osteoporosis Market, Bogutai® (Teriparatide Injection) Has Been Officially Approved By The China National Medical Products Administration (NMPA)
2020-09-18
Uni-Bio Science Group’s Uni-GLP Developmental Potential in Treatment of COVID-19 and Other Indications
2020-11-13
Uni-Bio Science Group Chairman Awarded “Young Industrialist of Hong Kong 2020”
2021-09-01
Uni-Bio Science Group and Alephoson Biopharmaceuticals Announce Partnership to Co-Develop Next-generation Best-in-class Compounds
2020-05-14
Uni-Bio Science Group and Medlink Builds Strategic Partnership,Expansion of Value Chain towards Pharmaceutical E-commerce
Contact
Message
HK Uni-Bio Science Group
乐虎lehu国际:(852)31023232
乐虎lehu国际:info@netruz.com
Unit 502, 5/F, No. 20 Science Park East Avenue,Hong Kong Science Park,Shatin, New Territories, Hong Kong
Shenzhen Watsin
(0755)21376639
乐虎lehu国际:info.ws@netruz.com
No.7 Science Middle 1st Road, Nanshan District, Shenzhen City
Uni-Bio YongTai
乐虎lehu国际:(010)80117799-8025
乐虎lehu国际:info.hc@netruz.com
1105, 10th floor, building 3, yard 93, Jianguo Road, Chaoyang District, Beijing
Beijing Genetech
乐虎lehu国际:(010)80117799
乐虎lehu国际:info.gt@netruz.com
No.7 Xinghuo Street, Changping Sector of Zhongguancun Science Park, Changping District, Beijing
Follow Us
Copyright ©2024 Uni-Bio Science Group Ltd.